Edwards Q1 sales $1.6B (+10%), TMTT +75%; raises FY sales guidance to high end 8-10%

Edwards Lifesciences Corp

2024-Q1 EPS reported $0.58 revenue$1,598,200,000

Q1 sales $1.6B, up 10% reported and constant currency; GAAP EPS $0.58, adjusted EPS $0.66.
TAVR sales $1.0B (+6% reported, +8% constant currency adjusted for billing days).
TMTT sales $73M (+75%); EVOQUE received FDA approval for tricuspid regurgitation in Feb.
Full-year 2024 sales guidance raised to high end of 8-10% range; TMTT guidance raised to $320-340M.
Critical Care spin-off on track; full-year adjusted EPS guidance maintained at $2.70-$2.80.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.